Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NHMEU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
T-Py-DM1
|
|||||
| Synonyms |
T Py DM1
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Neuroblastoma [ICD11:2A00]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2-3
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Oncodevelopmental antigen polysialic acid (polySia)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
TCO-PEG3-Mal
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 100 nM | Negative HER2 expression (HER2 -) | ||
| Method Description |
Cells were plated at 5,000, 2,500, and 2,500 cells/well, respectively, and allowed to rest for 24 h. Five-fold serial dilutions of the antibodies were added starting at 150 nM and incubated for 72-144 h.
|
||||
| In Vitro Model | Bone marrow neuroblastoma | SH-SY5Y cells | CVCL_0019 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 144 nM | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
Cells were plated at 5,000, 2,500, and 2,500 cells/well, respectively, and allowed to rest for 24 h. Five-fold serial dilutions of the antibodies were added starting at 150 nM and incubated for 72-144 h.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.